Supernus Pharmaceuticals Stock Market Value
| SUPN Stock | USD 36.57 0.42 1.14% |
| Symbol | Supernus |
Supernus Pharmaceuticals Price To Book Ratio
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share 1.07 | Revenue Per Share 11.877 | Quarterly Revenue Growth 0.142 | Return On Assets 0.0289 |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Supernus Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Supernus Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Supernus Pharmaceuticals.
| 01/09/2023 |
| 11/29/2024 |
If you would invest 0.00 in Supernus Pharmaceuticals on January 9, 2023 and sell it all today you would earn a total of 0.00 from holding Supernus Pharmaceuticals or generate 0.0% return on investment in Supernus Pharmaceuticals over 690 days. Supernus Pharmaceuticals is related to or competes with Haleon Plc, and Intracellular. Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of product... More
Supernus Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Supernus Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Supernus Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.11 | |||
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 12.87 | |||
| Value At Risk | (2.71) | |||
| Potential Upside | 2.77 |
Supernus Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Supernus Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Supernus Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Supernus Pharmaceuticals historical prices to predict the future Supernus Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0469 | |||
| Jensen Alpha | (0.03) | |||
| Total Risk Alpha | (0.21) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.089 |
Supernus Pharmaceuticals Backtested Returns
As of now, Supernus Stock is very steady. Supernus Pharmaceuticals owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.0586, which indicates the firm had a 0.0586% return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Supernus Pharmaceuticals, which you can use to evaluate the volatility of the company. Please validate Supernus Pharmaceuticals' Semi Deviation of 2.01, risk adjusted performance of 0.0469, and Coefficient Of Variation of 1887.5 to confirm if the risk estimate we provide is consistent with the expected return of 0.12%. Supernus Pharmaceuticals has a performance score of 4 on a scale of 0 to 100. The entity has a beta of 1.11, which indicates a somewhat significant risk relative to the market. Supernus Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Supernus Pharmaceuticals is expected to follow. Supernus Pharmaceuticals right now has a risk of 2.09%. Please validate Supernus Pharmaceuticals potential upside, as well as the relationship between the accumulation distribution and period momentum indicator , to decide if Supernus Pharmaceuticals will be following its existing price patterns.
Auto-correlation | -0.46 |
Modest reverse predictability
Supernus Pharmaceuticals has modest reverse predictability. Overlapping area represents the amount of predictability between Supernus Pharmaceuticals time series from 9th of January 2023 to 20th of December 2023 and 20th of December 2023 to 29th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Supernus Pharmaceuticals price movement. The serial correlation of -0.46 indicates that about 46.0% of current Supernus Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.46 | |
| Spearman Rank Test | -0.58 | |
| Residual Average | 0.0 | |
| Price Variance | 9.26 |
Supernus Pharmaceuticals lagged returns against current returns
Autocorrelation, which is Supernus Pharmaceuticals stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Supernus Pharmaceuticals' stock expected returns. We can calculate the autocorrelation of Supernus Pharmaceuticals returns to help us make a trade decision. For example, suppose you find that Supernus Pharmaceuticals has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Supernus Pharmaceuticals regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Supernus Pharmaceuticals stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Supernus Pharmaceuticals stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Supernus Pharmaceuticals stock over time.
Current vs Lagged Prices |
| Timeline |
Supernus Pharmaceuticals Lagged Returns
When evaluating Supernus Pharmaceuticals' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Supernus Pharmaceuticals stock have on its future price. Supernus Pharmaceuticals autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Supernus Pharmaceuticals autocorrelation shows the relationship between Supernus Pharmaceuticals stock current value and its past values and can show if there is a momentum factor associated with investing in Supernus Pharmaceuticals.
Regressed Prices |
| Timeline |
Pair Trading with Supernus Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Supernus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Supernus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Supernus Stock
| 0.78 | FNMFO | Federal National Mortgage Upward Rally | PairCorr |
Moving against Supernus Stock
| 0.87 | HLN | Haleon plc | PairCorr |
| 0.74 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.67 | BCH | Banco De Chile | PairCorr |
| 0.65 | ANRO | Alto Neuroscience, | PairCorr |
| 0.59 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
The ability to find closely correlated positions to Supernus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Supernus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Supernus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Supernus Pharmaceuticals to buy it.
The correlation of Supernus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Supernus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Supernus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Supernus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Supernus Pharmaceuticals Correlation, Supernus Pharmaceuticals Volatility and Supernus Pharmaceuticals Alpha and Beta module to complement your research on Supernus Pharmaceuticals. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Supernus Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.